SidaSubSaharaV1, Main, Exploration, bibRecordById, PMC:2569418

Duration from seroconversion to eligibility for antiretroviral therapy and from ART eligibility to death in adult HIV-infected patients from low and middle-income countries: collaborative analysis of prospective studies

Identifieur interne : 006178 ( Main/Exploration ); précédent : 006177; suivant : 006179

Duration from seroconversion to eligibility for antiretroviral therapy and from ART eligibility to death in adult HIV-infected patients from low and middle-income countries: collaborative analysis of prospective studies

Auteurs :

Source :

Sexually Transmitted Infections [ 1368-4973 ] ; 2008-08.

RBID : ISTEX:5B0FC4367EF7D228FCD6D15EF0EF28970A0AA655

Descripteurs français

Wicri :
- geographic : Thaïlande, Ouganda.
- topic : Critère d'éligibilité.

English descriptors

Abstract

Background: Estimation of the number of people in need of antiretroviral therapy (ART) in resource-limited settings requires information on the time from seroconversion to ART eligibility and from ART eligibility to death. Objectives: To estimate duration from seroconversion to different ART eligibility criteria and from ART eligibility to death in HIV-infected adults in low-income and middle-income countries. Methods: Participants with documented seroconversion from five cohorts (two cohorts from Uganda, two from Thailand and one from Côte d’Ivoire) were analysed. We used Weibull survival models and Bayesian simulation methods to model true (unobserved) first time of treatment eligibility. We set a consistency constraint so that the mean duration from seroconversion to death was equal to the mean from seroconversion to ART eligibility plus the mean from eligibility to death. Results: We analysed data from 2072 participants, 16 157 person-years of follow-up and 794 deaths. For the criterion CD4 T-lymphocyte count <200 cells ×106/l, the median duration from seroconversion to ART eligibility was 6.1 years (95% credibility interval 3.3–10.4) for all studies and 7.6 years (95% credibility interval 3.4–15.2) for all but the Thai cohorts. Corresponding estimates for the time from CD4 T-lymphocyte count <200 cells ×106/l to death were 2.1 years (0.7–4.8) and 2.7 years (0.8–8.4). When including all cohorts, the mean time from serconversion to CD4 T-lymphocyte count <200 cells ×106/l and from CD4 T-lymphocyte count <200 cells ×106/l to death represented 66% (38–87%) and 34% (13–62%), respectively of the total survival time. Conclusions: The duration of different ART eligibility criteria to death was longer than the estimates used in previous calculations of the number of people needing ART. However, uncertainty in estimates was considerable and heterogeneity across cohorts important.

Url:

DOI: 10.1136/sti.2008.029793

Affiliations:

Le document en format XML

<record><TEI wicri:istexFullTextTei="biblStruct"><teiHeader><fileDesc><titleStmt><title xml:lang="en">Duration from seroconversion to eligibility for antiretroviral therapy and from ART eligibility to death in adult HIV-infected patients from low and middle-income countries: collaborative analysis of prospective studies</title>
</titleStmt>
<publicationStmt><idno type="wicri:source">ISTEX</idno>
<idno type="RBID">ISTEX:5B0FC4367EF7D228FCD6D15EF0EF28970A0AA655</idno>
<date when="2008" year="2008">2008</date>
<idno type="doi">10.1136/sti.2008.029793</idno>
<idno type="url">https://api.istex.fr/document/5B0FC4367EF7D228FCD6D15EF0EF28970A0AA655/fulltext/pdf</idno>
<idno type="wicri:Area/Istex/Corpus">001D73</idno>
<idno type="wicri:explorRef" wicri:stream="Istex" wicri:step="Corpus" wicri:corpus="ISTEX">001D73</idno>
<idno type="wicri:Area/Istex/Curation">001D73</idno>
<idno type="wicri:Area/Istex/Checkpoint">001E59</idno>
<idno type="wicri:explorRef" wicri:stream="Istex" wicri:step="Checkpoint">001E59</idno>
<idno type="wicri:source">PMC</idno>
<idno type="url">http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2569418</idno>
<idno type="RBID">PMC:2569418</idno>
<idno type="wicri:Area/Pmc/Corpus">002C73</idno>
<idno type="wicri:explorRef" wicri:stream="Pmc" wicri:step="Corpus" wicri:corpus="PMC">002C73</idno>
<idno type="wicri:Area/Pmc/Curation">002C72</idno>
<idno type="wicri:explorRef" wicri:stream="Pmc" wicri:step="Curation">002C72</idno>
<idno type="wicri:Area/Pmc/Checkpoint">002A14</idno>
<idno type="wicri:explorRef" wicri:stream="Pmc" wicri:step="Checkpoint">002A14</idno>
<idno type="wicri:Area/Ncbi/Merge">000588</idno>
<idno type="wicri:Area/Ncbi/Curation">000588</idno>
<idno type="wicri:Area/Ncbi/Checkpoint">000588</idno>
<idno type="wicri:Area/Main/Merge">006272</idno>
<idno type="wicri:Area/Main/Curation">006178</idno>
<idno type="wicri:Area/Main/Exploration">006178</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title level="a" type="main" xml:lang="en">Duration from seroconversion to eligibility for antiretroviral therapy and from ART eligibility to death in adult HIV-infected patients from low and middle-income countries: collaborative analysis of prospective studies</title>
</analytic>
<monogr></monogr>
<series><title level="j">Sexually Transmitted Infections</title>
<title level="j" type="abbrev">Sex Transm Infect</title>
<idno type="ISSN">1368-4973</idno>
<idno type="eISSN">1472-3263</idno>
<imprint><publisher>BMJ Publishing Group Ltd</publisher>
<date type="published" when="2008-08">2008-08</date>
<biblScope unit="volume">84</biblScope>
<biblScope unit="issue">Suppl 1</biblScope>
<biblScope unit="page" from="31">i31</biblScope>
</imprint>
<idno type="ISSN">1368-4973</idno>
</series>
</biblStruct>
</sourceDesc>
<seriesStmt><idno type="ISSN">1368-4973</idno>
</seriesStmt>
</fileDesc>
<profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Active antiretroviral therapy</term>
<term>Additional analysis</term>
<term>Aids rangsin</term>
<term>Alpha network</term>
<term>Antiretroviral</term>
<term>Antiretroviral therapy</term>
<term>Available information</term>
<term>Blood donors</term>
<term>Cell count</term>
<term>Clinical stage</term>
<term>Cohort</term>
<term>Collaborative analysis</term>
<term>Community cohort</term>
<term>Confidence interval</term>
<term>Confidence intervals</term>
<term>Consistency constraint</term>
<term>Cote</term>
<term>Cotrimoxazole prophylaxis</term>
<term>Credibility</term>
<term>Credibility interval</term>
<term>Credibility intervals</term>
<term>Different eligibility criteria</term>
<term>Disease progression</term>
<term>Eligibility</term>
<term>Eligibility criteria</term>
<term>Estimate coverage</term>
<term>Exact date</term>
<term>First time</term>
<term>Hazard ratios</term>
<term>Individual participant data</term>
<term>Individual patient data</term>
<term>Literature review</term>
<term>Male blood donors</term>
<term>Median</term>
<term>Median duration</term>
<term>Model parameters</term>
<term>Mortality patterns</term>
<term>Nations programme</term>
<term>Natural history</term>
<term>Northern thailand</term>
<term>Preventive medicine</term>
<term>Public health approach</term>
<term>Random effects</term>
<term>Relevant criteria</term>
<term>Rural uganda</term>
<term>Seroconversion</term>
<term>Seroconverter cohorts</term>
<term>Survival distributions</term>
<term>Survival times</term>
<term>Systematic reviews</term>
<term>Thai</term>
<term>Thai cohorts</term>
<term>Thai studies</term>
<term>Thailand</term>
<term>Time intervals</term>
<term>Time points</term>
<term>Total time</term>
<term>Transm</term>
<term>Treatment eligibility</term>
<term>Uganda</term>
<term>Universal access</term>
<term>World health organization</term>
<term>Years years</term>
</keywords>
<keywords scheme="Teeft" xml:lang="en"><term>Active antiretroviral therapy</term>
<term>Additional analysis</term>
<term>Aids rangsin</term>
<term>Alpha network</term>
<term>Antiretroviral</term>
<term>Antiretroviral therapy</term>
<term>Available information</term>
<term>Blood donors</term>
<term>Cell count</term>
<term>Clinical stage</term>
<term>Cohort</term>
<term>Collaborative analysis</term>
<term>Community cohort</term>
<term>Confidence interval</term>
<term>Confidence intervals</term>
<term>Consistency constraint</term>
<term>Cote</term>
<term>Cotrimoxazole prophylaxis</term>
<term>Credibility</term>
<term>Credibility interval</term>
<term>Credibility intervals</term>
<term>Different eligibility criteria</term>
<term>Disease progression</term>
<term>Eligibility</term>
<term>Eligibility criteria</term>
<term>Estimate coverage</term>
<term>Exact date</term>
<term>First time</term>
<term>Hazard ratios</term>
<term>Individual participant data</term>
<term>Individual patient data</term>
<term>Literature review</term>
<term>Male blood donors</term>
<term>Median</term>
<term>Median duration</term>
<term>Model parameters</term>
<term>Mortality patterns</term>
<term>Nations programme</term>
<term>Natural history</term>
<term>Northern thailand</term>
<term>Preventive medicine</term>
<term>Public health approach</term>
<term>Random effects</term>
<term>Relevant criteria</term>
<term>Rural uganda</term>
<term>Seroconversion</term>
<term>Seroconverter cohorts</term>
<term>Survival distributions</term>
<term>Survival times</term>
<term>Systematic reviews</term>
<term>Thai</term>
<term>Thai cohorts</term>
<term>Thai studies</term>
<term>Thailand</term>
<term>Time intervals</term>
<term>Time points</term>
<term>Total time</term>
<term>Transm</term>
<term>Treatment eligibility</term>
<term>Uganda</term>
<term>Universal access</term>
<term>World health organization</term>
<term>Years years</term>
</keywords>
<keywords scheme="Wicri" type="geographic" xml:lang="fr"><term>Thaïlande</term>
<term>Ouganda</term>
</keywords>
<keywords scheme="Wicri" type="topic" xml:lang="fr"><term>Critère d'éligibilité</term>
</keywords>
</textClass>
<langUsage><language ident="en">en</language>
</langUsage>
</profileDesc>
</teiHeader>
<front><div type="abstract">Background: Estimation of the number of people in need of antiretroviral therapy (ART) in resource-limited settings requires information on the time from seroconversion to ART eligibility and from ART eligibility to death. Objectives: To estimate duration from seroconversion to different ART eligibility criteria and from ART eligibility to death in HIV-infected adults in low-income and middle-income countries. Methods: Participants with documented seroconversion from five cohorts (two cohorts from Uganda, two from Thailand and one from Côte d’Ivoire) were analysed. We used Weibull survival models and Bayesian simulation methods to model true (unobserved) first time of treatment eligibility. We set a consistency constraint so that the mean duration from seroconversion to death was equal to the mean from seroconversion to ART eligibility plus the mean from eligibility to death. Results: We analysed data from 2072 participants, 16 157 person-years of follow-up and 794 deaths. For the criterion CD4 T-lymphocyte count <200 cells ×106/l, the median duration from seroconversion to ART eligibility was 6.1 years (95% credibility interval 3.3–10.4) for all studies and 7.6 years (95% credibility interval 3.4–15.2) for all but the Thai cohorts. Corresponding estimates for the time from CD4 T-lymphocyte count <200 cells ×106/l to death were 2.1 years (0.7–4.8) and 2.7 years (0.8–8.4). When including all cohorts, the mean time from serconversion to CD4 T-lymphocyte count <200 cells ×106/l and from CD4 T-lymphocyte count <200 cells ×106/l to death represented 66% (38–87%) and 34% (13–62%), respectively of the total survival time. Conclusions: The duration of different ART eligibility criteria to death was longer than the estimates used in previous calculations of the number of people needing ART. However, uncertainty in estimates was considerable and heterogeneity across cohorts important.</div>
</front>
</TEI>
<affiliations><list></list>
<tree></tree>
</affiliations>
</record>

Pour manipuler ce document sous Unix (Dilib)

EXPLOR_STEP=$WICRI_ROOT/Wicri/Sante/explor/SidaSubSaharaV1/Data/Main/Exploration

HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 006178 | SxmlIndent | more

HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 006178 | SxmlIndent | more

Pour mettre un lien sur cette page dans le réseau Wicri

{{Explor lien
   |wiki=    Wicri/Sante
   |area=    SidaSubSaharaV1
   |flux=    Main
   |étape=   Exploration
   |type=    RBID
   |clé=     ISTEX:5B0FC4367EF7D228FCD6D15EF0EF28970A0AA655
   |texte=   Duration from seroconversion to eligibility for antiretroviral therapy and from ART eligibility to death in adult HIV-infected patients from low and middle-income countries: collaborative analysis of prospective studies
}}

This area was generated with Dilib version V0.6.32.
Data generation: Mon Nov 13 19:31:10 2017. Site generation: Wed Mar 6 19:14:32 2024

Le SIDA en Afrique subsaharienne (serveur d'exploration)

Duration from seroconversion to eligibility for antiretroviral therapy and from ART eligibility to death in adult HIV-infected patients from low and middle-income countries: collaborative analysis of prospective studies

Duration from seroconversion to eligibility for antiretroviral therapy and from ART eligibility to death in adult HIV-infected patients from low and middle-income countries: collaborative analysis of prospective studies

Source :

Descripteurs français

English descriptors

Abstract

Links toward previous steps (curation, corpus...)

Le document en format XML

Pour manipuler ce document sous Unix (Dilib)

Pour mettre un lien sur cette page dans le réseau Wicri

	Le SIDA en Afrique subsaharienne (serveur d'exploration)
	Attention, ce site est en cours de développement ! Attention, site généré par des moyens informatiques à partir de corpus bruts. Les informations ne sont donc pas validées.